Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | MET | P08581 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528444 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2BMETKDM4EPDE4A | |
| SCHEMBL26529143 | 0.92 | MET (0.46) | GRIN1GRIN2BMETKDM4EPDE4A | |
| SCHEMBL26527912 | 0.92 | MET (0.46) | GRIN1GRIN2BMETKDM4EPDE4A | |
| SCHEMBL26999003 | 0.89 | PDE4B (0.54) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26999081 | 0.87 | MAPT (0.47) | GRIN1GRIN2BMETKDM4EPDE4A | |
| SCHEMBL26999002 | 0.85 | MET (0.52) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29569798 | 0.84 | GRIN2B (0.50) | GRIN1GRIN2BMETMEN1KMT2A | |
| SCHEMBL23528379 | 0.84 | GRIN2B (0.50) | GRIN1GRIN2BMETMEN1KMT2A | |
| SCHEMBL29776802 | 0.84 | HDAC1 (0.45) | GRIN1GRIN2BKDM4EPDE4APDE4B | |
| SCHEMBL23297366 | 0.84 | HDAC1 (0.45) | GRIN1GRIN2BKDM4EPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220106291-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012395-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | GRIN1 894/4885GRIN2B 1997/4885MET 4212/4885 |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | GRIN1 894/4885GRIN2B 1997/4885MET 4212/4885 |
| US-20220106291-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | GRIN1 894/4885GRIN2B 1997/4885MET 4212/4885 |
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | GRIN1 894/4885GRIN2B 1997/4885MET 4212/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | GRIN1 894/4885GRIN2B 1997/4885MET 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.